MA27032A1 - Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6 - Google Patents

Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6

Info

Publication number
MA27032A1
MA27032A1 MA27422A MA27422A MA27032A1 MA 27032 A1 MA27032 A1 MA 27032A1 MA 27422 A MA27422 A MA 27422A MA 27422 A MA27422 A MA 27422A MA 27032 A1 MA27032 A1 MA 27032A1
Authority
MA
Morocco
Prior art keywords
receptor
new indole
affinity
derivatives
affinity derivatives
Prior art date
Application number
MA27422A
Other languages
English (en)
Inventor
Colin Charles Beard
Robin Douglas Clark
Lawrence Emerson Fisher
Ralph New Harris Iii
David Bruce Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27032A1 publication Critical patent/MA27032A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA27422A 2001-06-07 2003-12-03 Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6 MA27032A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29670501P 2001-06-07 2001-06-07
US34021201P 2001-12-13 2001-12-13

Publications (1)

Publication Number Publication Date
MA27032A1 true MA27032A1 (fr) 2004-12-20

Family

ID=26969776

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27422A MA27032A1 (fr) 2001-06-07 2003-12-03 Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6

Country Status (32)

Country Link
US (3) US6787535B2 (fr)
EP (1) EP1401813B1 (fr)
JP (1) JP4187642B2 (fr)
KR (1) KR100600240B1 (fr)
CN (1) CN1257892C (fr)
AR (1) AR036233A1 (fr)
AT (1) ATE353318T1 (fr)
AU (1) AU2002310747B2 (fr)
BG (1) BG108420A (fr)
BR (1) BR0210929A (fr)
CA (1) CA2449874C (fr)
CO (1) CO5630036A2 (fr)
CZ (1) CZ20033529A3 (fr)
DE (1) DE60218037T2 (fr)
ES (1) ES2280546T3 (fr)
HR (1) HRP20030984A2 (fr)
HU (1) HUP0401307A2 (fr)
IL (1) IL158997A0 (fr)
MA (1) MA27032A1 (fr)
MX (1) MXPA03011244A (fr)
NO (1) NO20035359D0 (fr)
NZ (1) NZ529631A (fr)
PA (1) PA8546601A1 (fr)
PE (1) PE20030039A1 (fr)
PL (1) PL367305A1 (fr)
RU (1) RU2294932C2 (fr)
SK (1) SK16052003A3 (fr)
TW (1) TW591015B (fr)
UY (1) UY27322A1 (fr)
WO (1) WO2002098857A1 (fr)
YU (1) YU96103A (fr)
ZA (1) ZA200309005B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100457726C (zh) 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
US20040242589A1 (en) * 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897881A3 (fr) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
CN1662521A (zh) * 2002-06-20 2005-08-31 比奥维特罗姆股份公司 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物
CN1314669C (zh) 2002-09-17 2007-05-09 弗·哈夫曼-拉罗切有限公司 2,7－取代的吲哚以及它们作为5－ht6调节剂的用途
WO2004074286A1 (fr) * 2003-02-14 2004-09-02 Wyeth Derives de heterocyclyl-3-sulfonylazaindole ou -azaindazole utilises comme ligands de la 5-hydroxytryptamine-6
WO2004087156A1 (fr) 2003-04-04 2004-10-14 H. Lundbeck A/S Derives 4-(2-phenylsulfanyl-phenyl)-piperidines utilises en tant qu'inhibiteurs de reabsorption de la serotonine
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
KR20060127886A (ko) * 2003-12-19 2006-12-13 바이오비트럼 에이비 5-ｈｔ6 수용체-관련 장애의 예방 및 치료에 사용될 수있는, 신규한 벤조퓨란 유도체
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
EP1694323A4 (fr) * 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc Procedes de traitement d'un trouble
EP1701940B1 (fr) 2003-12-23 2008-05-28 H.Lundbeck A/S Dérivés de 2-(1h-indolylsulfanyl)-benzyl amine comme ssri
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
TW200616967A (en) * 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1799306B1 (fr) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions et procedes pour le traitement de troubles cognitifs
WO2006062481A1 (fr) * 2004-12-09 2006-06-15 Biovitrum Ab Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2619010C (fr) * 2005-08-15 2013-10-01 Wyeth Derives de 3-sulfonylindazole substitues en tant que ligands de 5-hydroxytryptamine-6
ES2274725B1 (es) * 2005-11-08 2008-04-01 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
JP2009523734A (ja) * 2006-01-13 2009-06-25 ワイス ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール
EP1984351A1 (fr) * 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Composes ayant une affinite pour le recepteur 5-ht6
MX2009004898A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
KR101176894B1 (ko) * 2007-01-08 2012-08-30 수벤 라이프 사이언시스 리미티드 ４?（헤테로시클릴）알킬?ｎ?（아릴술포닐） 인돌 화합물 및 이들의 ５?ｈｔ６ 리간드로서 용도
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
AU2008216032A1 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6 ' substituted indole and indazole derivatives having 5-HT6 receptor affinity
EP2120950B1 (fr) * 2007-03-21 2012-07-04 Glaxo Group Limited Utilisation de derives quinoleines pour le traitement de la douleur
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
AU2008246947B2 (en) 2007-05-03 2011-03-31 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
KR20100031578A (ko) * 2007-05-24 2010-03-23 메모리 파마슈티칼스 코포레이션 5-ｈｔ6 수용체 친화성을 갖는 4'-치환된 화합물
WO2009023844A2 (fr) * 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation Composés substitués en position 3' ayant une affinité vis-à-vis du récepteur 5-ht6
CA2703157C (fr) 2007-10-26 2013-02-05 Suven Life Sciences Limited Composes d'aminoarylsulfonamide et leur utilisation comme ligands de 5-ht6
EP2254564A1 (fr) 2007-12-12 2010-12-01 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
KR20100101171A (ko) * 2008-02-15 2010-09-16 에프. 호프만-라 로슈 아게 3-알킬-피페라진 유도체 및 이의 용도
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
MX2011002884A (es) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
EP2606031B1 (fr) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Inhibiteurs de l'autotaxine et leurs utilisations
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CN102924359B (zh) * 2012-10-30 2015-03-11 中国科学院烟台海岸带研究所 一种一锅法合成取代吲哚类化合物的方法
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124206C (fr) * 1991-11-25 2001-02-27 John Eugene Macor Derives indole
CA2194984C (fr) 1994-07-26 2002-07-02 John Eugene Macor Derives 4-indole utilises comme agonistes et antagonistes de la serotonine
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU732863B2 (en) * 1997-04-18 2001-05-03 Smithkline Beecham Plc Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
EP1173432B9 (fr) * 1999-04-21 2008-10-15 NPS Allelix Corp. Composes piperidine-indol ayant une affinite avec 5-ht6
WO2001032660A1 (fr) * 1999-11-05 2001-05-10 Nps Allelix Corp. Composes ayant une activite d'antagoniste de recepteur de 5-ht¿6?
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1343756A2 (fr) * 2000-11-02 2003-09-17 Wyeth 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
EA200300717A1 (ru) * 2000-12-22 2003-12-25 Уайт Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ES2264994T3 (es) * 2000-12-22 2007-02-01 Wyeth Compuestos heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6.
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
KR20030088508A (ko) * 2001-04-20 2003-11-19 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴옥시-, -티옥시- 및 -아미노벤즈아졸 유도체
US20040242589A1 (en) * 2001-08-07 2004-12-02 Bromidge Steven Mark 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2006505559A (ja) * 2002-10-18 2006-02-16 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール

Also Published As

Publication number Publication date
US20050171118A1 (en) 2005-08-04
RU2003136731A (ru) 2005-05-20
MXPA03011244A (es) 2004-02-27
PA8546601A1 (es) 2003-01-24
RU2294932C2 (ru) 2007-03-10
CA2449874C (fr) 2009-06-23
ZA200309005B (en) 2005-02-21
UY27322A1 (es) 2003-02-28
KR100600240B1 (ko) 2006-07-13
IL158997A0 (en) 2004-05-12
WO2002098857A1 (fr) 2002-12-12
BG108420A (en) 2005-02-28
CN1527816A (zh) 2004-09-08
ATE353318T1 (de) 2007-02-15
JP4187642B2 (ja) 2008-11-26
ES2280546T3 (es) 2007-09-16
BR0210929A (pt) 2004-06-08
CO5630036A2 (es) 2006-04-28
SK16052003A3 (en) 2004-10-05
HUP0401307A2 (hu) 2004-12-28
DE60218037T2 (de) 2007-08-23
EP1401813B1 (fr) 2007-02-07
US6787535B2 (en) 2004-09-07
US20030073700A1 (en) 2003-04-17
KR20040004702A (ko) 2004-01-13
CN1257892C (zh) 2006-05-31
YU96103A (sh) 2006-08-17
NO20035359D0 (no) 2003-12-02
PE20030039A1 (es) 2003-02-13
NZ529631A (en) 2006-08-31
US20040248902A1 (en) 2004-12-09
HRP20030984A2 (en) 2005-10-31
AU2002310747B2 (en) 2007-10-11
CA2449874A1 (fr) 2002-12-12
PL367305A1 (en) 2005-02-21
JP2004533460A (ja) 2004-11-04
WO2002098857A8 (fr) 2004-04-22
TW591015B (en) 2004-06-11
CZ20033529A3 (cs) 2004-04-14
AR036233A1 (es) 2004-08-25
HK1068610A1 (en) 2005-04-29
DE60218037D1 (de) 2007-03-22
EP1401813A1 (fr) 2004-03-31

Similar Documents

Publication Publication Date Title
IL158997A0 (en) New indole derivatives with 5-ht6 receptor affinity
ATE331707T1 (de) 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor
FI973205A0 (fi) Indolijohdannaisia 5-HT-reseptoriantagonisteina
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DK1189916T3 (da) N-pyrazol A 2A-receptoragonister
DE60030035D1 (de) Mehrschichtige Struktur
ATE344030T1 (de) 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
DE60023167T2 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE60033545D1 (de) Neue bizyklische cannabinoid-agonisten für den cannabinoid-rezeptor
NO20026168D0 (no) 3-azabicyklo(3.1.0)heksan derivater med opioid reseptor affinitet
EP1470357A4 (fr) Bride pour raccordement d&#39;elements tubulaires
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
DZ3333A1 (fr) Antagonistes de recepteurs d&#39;il-8
FR2824826B1 (fr) Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l&#39;interleukine-8
MA27240A1 (fr) Derives d&#39;imidazoquinoleine
EP1434604A4 (fr) 4-halo-ethenylphenyltropane: agents d&#39;imagerie pour les transporteurs de serotonine
FR2824622B3 (fr) Anneau de liaison pour projecteur de vehicules
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
ATE237420T1 (de) Giessrohr
ATE304007T1 (de) Neue indolderivate
FR2819550B1 (fr) Pot silencieux d&#39;echappement pour motocyclette
FR2820249B1 (fr) Moyen d&#39;accrochage pour ligne aerienne
EP1353108A4 (fr) Raccord pour joint de tuyaux
FR2830523B1 (fr) Support pour selles d&#39;equitation